ClinicalTrials.gg
RecruitingNCT06573008Updated Dec 4, 2024

Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

A Phase 3 interventional study of GP681 40mg and GP681 Simulant in Influenza, Human, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-04.

Sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. (part of Qingfeng Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Planned enrollment
81st of 157
328 · median 360
Started
2024
with 16 others
Phase 3
46 of 173
9 open now
Primary completion
2025-12
later than 14 of 36 live
Registered
131st of 173
by date
Lead sponsor
7 of 173
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Among the 173 studies in Influenza, Human with a site in China, this one is the 81st largest by planned enrollment of the 157 interventional ones that give a count, is one of 17 that started in 2024, is one of 46 in phase 3, reaches primary completion later than 14 of the 36 other live ones, and was the 131st registered.

Influenza, Human

2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.

03

Conditions studied

  • Influenza, Human

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged ≥12 years at the time of signing the form.
  2. Patients with a diagnosis of influenza confirmed by all of the following:

    • Positive throat or nose swab by rapid influenza antigen test (RAT) (where rapid influenza virus nucleic acid test or other rapid molecular diagnostic methods are also acceptable);

      • Fever (axillary temperature ≥37.3℃) in the predose examinations or > 4 hours after dosing of antipyretics if they were taken;

        • At least one of the following systemic symptoms and respiratory symptoms respectively associated with influenza are present with a severity of moderate or greater:

    Systemic symptoms: headache, fever or chills, muscle or joint aches, fatigue; Respiratory system symptoms: cough, sore throat, nasal congestion.

  3. The time interval between the onset of symptoms and random enrollment is 48 hours or less. The onset of symptoms is defined as either:

    1. Time of the first increase in body temperature (axillary temperature ≥37.3℃)
    2. Time when the patient experiences at least 1 new general or respiratory symptom related to influenza
  4. Referring to the standards of the Centers for Disease Control and Prevention (CDC) in the United States and the definition of high-risk populations for influenza complications in the "Expert Consensus on Diagnosis and Treatment of Influenza in Adults in the Emergency Department (2022 Edition)", that is, if at least one of the following criteria is met, the patient will be considered at high risk of influenza complications:

    1. Asthma or chronic lung diseases [such as (COPD), cystic fibrosis, chronic bronchitis, bronchiectasis, emphysema, chronic interstitial pneumonia, etc.];
    2. Endocrine disorders (including diabetes);
    3. Residents of long-term care institutions (such as nursing homes);
    4. Immune system impairment (including patients receiving chronic systemic treatment of ≤20mg/d prednisone or an equivalent dose);
    5. Neurological and neurodevelopmental disorders (including brain, spinal cord, peripheral nerve and muscle diseases, such as cerebral palsy, epilepsy (episodic disorders), stroke, muscular dystrophy or spinal cord injury);
    6. Heart diseases (such as congenital heart disease, congestive heart failure, or coronary artery disease), but not including hypertension without any other cardiac-related symptoms;
    7. Patients aged ≥65 years;
    8. Blood system diseases (such as sickle cell disease);
    9. Metabolic system diseases (such as hereditary metabolic diseases and mitochondrial diseases);
    10. Liver diseases (such as chronic , chronic , non-alcoholic steatohepatitis);
    11. Kidney diseases (estimated eGFR ≥ 30 mL/min/1.73m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula);
    12. Obese patients ( ≥ 30 kg/m2);
    13. Female patients within 2 weeks postpartum and not breastfeeding.
  5. Subjects of who agree to use a highly effective method of for 1 month after drug withdrawal.
  6. Subjects and/or their guardian who are willing to provide written informed consent and consent to participate in the study, able to understand the study and comply with all study procedures, including patient health diary records.

Exclusion criteria

Exclusion Criteria:

  1. History of allergic reactions attributed to GP681,Acetaminophen, bromohexine hydrochloride or any of the ingredients of its formulation.
  2. Known history of dysphagia or any gastrointestinal disease that affects drug absorption (including but not limited to chronic diarrhea, inflammatory bowel disease, tuberculosis of the intestines, gastrinoma, short bowel syndrome, postoperative gastrectomy, etc.);
  3. Screening patients who, in the opinion of the investigator, require hospitalization due to severe influenza virus infection;.
  4. Screening patients who, at the time of screening, are clinically diagnosed with bacterial or other viral infections requiring systemic antibacterial or antiviral treatment;
  5. Cancer patients who are currently receiving or have received chemotherapy or radiation therapy within the past year (excluding non-melanoma skin cancer and thyroid cancer)
  6. Known -infected patients;
  7. Organ or bone marrow transplant recipients;
  8. Patients who are currently receiving >20mg/d of prednisone or equivalent chronic systemic therapy;
  9. Patients who have used anti-influenza virus drugs (including neuraminidase inhibitors, hemagglutinin inhibitors, and M2 ion channel blockers, such as oseltamivir, zanamivir, palivizumab, favipiravir, abidol, marabolexavir, amantadine or rimantadine or other anti-influenza virus drugs approved by NMPA) within the past 2 weeks or who have received influenza vaccination within the past 6 months;
  10. Exclusion of participants who have received clinical research or screening within the past 30 days for any indication with a trial drug or device, or who have received clinical research for a monoclonal antibody drug for viral diseases within the past year;
  11. Known to have had a previous history of severe liver function impairment such as cirrhosis with ascites, hepatic encephalopathy, or a history of upper gastrointestinal bleeding;
  12. Estimated (eGFR) by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \<30mL/min/1.73m2 at the time of screening;
  13. Individuals with a history of alcohol abuse or substance abuse (more than 14 units of alcohol per week, 1 unit of alcohol = 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine with an alcohol content of 12%);
  14. Adult reproductive-age females who are pregnant or breastfeeding or who have a positive pregnancy test. Women who are infertile (i.e., women who have had a hysterectomy, bilateral oophorectomy, or tubal ligation for medical reasons or who are - defined as age > 50 years and menopause has occurred for at least 2 years) do not need a pregnancy test;
  15. Patients who, in the opinion of the Investigator, may not be qualified or suitable for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
328 participants (estimated)

Study arms

  • Experimental
    GP681 tablet 40mg

    Patients in the GP681 tablet 40mg group will receive a single oral dose of GP681 tablet 40mg.

    Drug: GP681 40mg

  • Placebo comparator
    Placebo group

    Patients in the Placebo group will receive a single oral dose of GP681 Simulant 40mg.

    Drug: GP681 Simulant

Interventions

  • DrugGP681Studies of GP681GP681 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2 x 20mg tablets taken orally

  • DrugGP681 Simulant

    Placebo tablets matching GP681 40mg

06

What researchers measure

Primary outcomes

  1. Time to alleviation of influenza symptoms

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Defined as the time from the start of treatment until the patient's body temperature returns to normal and all 7 flu symptoms (cough, sore throat, headache, nasal congestion, fever or chills, muscle or joint pain, fatigue) have alleviated (scoring 0 or 1 point), maintained, or improved, as defined below, for at duration of at least 21.5 hours. Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline Preexisting symptoms not worse at baseline must have maintained baseline severity New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1).

    Time frame: up to Day 15

Secondary outcomes

  1. Change From Baseline in Virus RNA (Q-PCR) at Each Time Point

    Nasopharyngeal swabs were obtained for viral quantitation.

    Time frame: Day 2, Day3, Day5, Day7

  2. Percentage of Participants With Positive Influenza Virus RNA by Q-PCR at Each Time Point

    The percentage of patients positive for virus RNA by RT-PCR.

    Time frame: Day 2, Day3, Day5, Day7

  3. Area Under the Concentration (AUC) of virus RNA by Q-PCR and AUC of virus titer

    AUC of the viral load by RT-PCR and AUC of viral titer measured from baseline to Day 7

    Time frame: Up to Day 7

  4. Change in the total score of 7 influenza symptoms

    The composite symptom score is the total score of the 7 influenza symptoms(Sum of symptom scores) as assessed by the participant, and ranges from 0 to 21.

    Time frame: Up to Day15

  5. Time to Cessation of Viral Shedding Determined by Virus Titer

    Defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection.

    Time frame: up to Day7

  6. Time to alleviation of each influenza symptom.

    Defined as the time from the start of the study treatment to the start of the time when the individual symptom was assessed by the participant as have alleviated (scoring 0 or 1 point), maintained, or improved , for at duration of at least 21.5 hours.

    Time frame: Up to Day15

  7. Time to Alleviation of the Three Respiratory Symptoms in Participants

    Defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours.

    Time frame: Up to Day15

  8. Time to Alleviation of the Four Systemic Symptoms in Participants

    Defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, for a duration of at least 21.5 hours.

    Time frame: Up to Day15

  9. Percentage of Participants Reporting Normal Temperature at Each Time Point

    Defined as the percentage of patients whose axillary temperature dropped to less than 37.3ºC after the initiation of study treatment

    Time frame: 12h, 24h,48h,72h,96h,120h,144h,168h

  10. Time to Resolution of Fever

    Defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37.3ºC and was maintained at less than 37.3ºC for a duration of at least 21.5 hours.

    Time frame: Up to Day15

  11. Incidence of influenza-related complications

    Defined as the percentage of subjects in the analysis population who experience each influenza-related complication (hospitalization, death, sinusitis, bronchitis, otitis media, and pneumonia) as an adverse event after the initiation of the study treatment.

    Time frame: Up to Day15

  12. Proportion of patients and frequency in combination use of acetaminophen.

    The proportion of patients who use acetaminophen in the duration of the study

    Time frame: Up to Day15

  13. The percentage of participants who received systemic antibiotics.

    The proportion of patients receiving systemic antibiotic therapy after treatment initiation.

    Time frame: Up to Day15

  14. The percentage of participants with secondary influenza infections after enrollment

    Defined as the percentage of subjects who develop secondary influenza infections after treatment initiation in the study population as an adverse event after the initiation of the study treatment

    Time frame: Up to Day15

  15. Time to Return to Preinfluenza Health Status

    Defined as the participant's pre-influenza daily activity score from the start of treatment until the participant's recovery to influenza. Subjects whose baseline self-reported daily activity score was higher than or equal to the pre-influenza score were excluded from the analysis.

    Time frame: Up to Day15

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2025, 13 months after the start.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 13 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2024
First posted
Aug 27, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Dec 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06573008
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Nov 11, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Dec 4, 2024

Study contacts

Siyuan Xi
Contact
ZRYHYYGCPEC@126.com
84206250
Bin Cao, phd
Contact
caobin_ben@163.com
13911318339

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GP681

Start the discussion